Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS): A Single-Center, Open-Label, Single-Arm, Dose-Escalation Investigator-Initiated Clinical Study

NCT07875972 is registered in ClinicalTrials.gov with Liu Qing as lead sponsor.

NCT NCT07875972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07875972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS): A Single-Center, Open-Label, Single-Arm, Dose-Escalation Investigator-Initiated Clinical Study
Lead sponsor
Liu Qing
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2028
Enrollment
12 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis (als)